Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data

Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.